937 related articles for article (PubMed ID: 11656912)
1. The IRB's role in assessing the generalizability of non-NIH-funded clinical trials.
Weijer C
IRB; 1998; 20(2-3):1-5. PubMed ID: 11656912
[No Abstract] [Full Text] [Related]
2. An IRB member's perspective on access to innovative therapy.
Moore DL
Albany Law Rev; 1994; 57(3):559-81. PubMed ID: 11652854
[No Abstract] [Full Text] [Related]
3. The concept of the IRB and bureaucratic reality: an exchange of letters.
van Eys J; Levine RJ
IRB; 1984; 6(4):8-10. PubMed ID: 11649563
[No Abstract] [Full Text] [Related]
4. The changing clinical trials scene: the role of the IRB.
Mitchell SC; Steingrub J
IRB; 1988; 10(4):1-5. PubMed ID: 11650078
[No Abstract] [Full Text] [Related]
5. The paradoxical case of payment as benefit to research subjects.
Macklin R
IRB; 1989; 11(6):1-3. PubMed ID: 11650284
[No Abstract] [Full Text] [Related]
6. The regulation of human experimentation in the United States--a personal odyssey.
Katz J
IRB; 1987; 9(1):1-6. PubMed ID: 11649890
[No Abstract] [Full Text] [Related]
7. Continuing review of research involving human subjects: approach to the problem and remaining areas of concern.
Gordon B; Prentice E
IRB; 1997; 19(2):8-11. PubMed ID: 11655323
[No Abstract] [Full Text] [Related]
8. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
Gordon VM; Sugarman J; Kass N
IRB; 1998; 20(1):1-5. PubMed ID: 11655324
[No Abstract] [Full Text] [Related]
9. Half-full or half-empty? Evaluating IRB performance.
Mishkin B; Ariand N
Prof Ethics Rep; 1998; 11(3):4-7. PubMed ID: 11657925
[No Abstract] [Full Text] [Related]
10. FDA's new rule on treatment use and sale of investigational new drugs.
Levine RJ
IRB; 1987; 9(4):1-4. PubMed ID: 11649946
[No Abstract] [Full Text] [Related]
11. Multicenter trials and subject eligibility: should local IRBs play a role?
Freedman B
IRB; 1994; 16(1-2):1-6. PubMed ID: 11652320
[No Abstract] [Full Text] [Related]
12. Considering experimentation and elusive truth: informed consent made difficult.
Brodeur D
Issues (St Louis Mo); 1992; 7(2):1-8. PubMed ID: 11659444
[No Abstract] [Full Text] [Related]
13. IRB review of adverse events in investigational drug studies.
Prentice ED; Gordon B
IRB; 1997; 19(6):1-4. PubMed ID: 11656910
[No Abstract] [Full Text] [Related]
14. Informed consent: the FDA's perspective.
Bagley G
Food Drug Law J; 1993; 48(2):181-6. PubMed ID: 11653141
[No Abstract] [Full Text] [Related]
15. Questions and answers.
Goodwin FK
J Calif Alliance Ment Ill; 1994; 5(1):45-7. PubMed ID: 11653321
[No Abstract] [Full Text] [Related]
16. Testing drugs in pediatric populations: the FDA mandate.
Tauer CA
Account Res; 1999; 7(1):37-58. PubMed ID: 11657562
[No Abstract] [Full Text] [Related]
17. Ethical issues in clinical neurological research.
Shore D; Berg K; Mullican C
J Calif Alliance Ment Ill; 1994; 5(1):61-2. PubMed ID: 11653329
[No Abstract] [Full Text] [Related]
18. IRBs and randomized clinical trials.
Meinert CL
IRB; 1998; 20(2-3):9-12. PubMed ID: 11656915
[No Abstract] [Full Text] [Related]
19. Federal report says protection of human subjects is threatened by numerous factors.
Maloney DM
Hum Res Rep; 1996 May; 11(5):1-3. PubMed ID: 11654438
[No Abstract] [Full Text] [Related]
20. Institutional review boards in the university setting: review of pharmaceutical testing protocols, informed consent and ethical concerns.
Kobasic DM
J Coll Univ Law; 1988; 15(2):185-216. PubMed ID: 11659168
[No Abstract] [Full Text] [Related]
[Next] [New Search]